TY - JOUR
T1 - Developing a European research network to address unmet needs in anxiety disorders
AU - Baldwin, David S.
AU - Pallanti, Stefano
AU - Zwanzger, Peter
N1 - Funding Information:
This paper is based on a talk given at the Hungarian Academy of Sciences in Budapest on18th March 2011, to coincide with the Hungarian Presidency of the European Union. The Anxiety Disorders Research Network is one component of the ECNP-Network Initiative (ECNP-NI) and has received financial support from the ECNP , to support the early stages of its development. * Current (December 2012) centres within the ADRN are located in Amsterdam, Bristol, Florence, Goettingen, Gothenberg, Groningen, Leiden, London, Milan, Munster, Paris, Pisa, Santander, Southampton, Stockholm, Tartu, Tel Aviv, Uppsala, Welwyn Garden City, Wurzburg, and Zurich.
PY - 2013/12
Y1 - 2013/12
N2 - Anxiety disorders are common, typically have an early onset, run a chronic or relapsing course, cause substantial personal distress, impair social and occupational function, reduce quality of life, and impose a substantial economic burden: they are often comorbid with major depression, bipolar disorder, schizophrenia, substance misuse and physical illness, and are associated with increased risks of suicidal behaviour. As such, anxiety disorders should be regarded as a significant public health problem. However the causes of anxiety disorders remain largely unknown, which hinders accurate diagnosis, the prediction of prognosis, and the development of refined treatment approaches. In clinical practice, many patients with anxiety disorders do not present or are not recognised, the standard of care they receive is often sub-optimal, and the effectiveness of pharmacological and psychological treatment interventions in real-world clinical practice can be disappointing. The current substantial unmet public health, clinical and research needs in anxiety disorders could be addressed in part by developing independent collaborative European networks.
AB - Anxiety disorders are common, typically have an early onset, run a chronic or relapsing course, cause substantial personal distress, impair social and occupational function, reduce quality of life, and impose a substantial economic burden: they are often comorbid with major depression, bipolar disorder, schizophrenia, substance misuse and physical illness, and are associated with increased risks of suicidal behaviour. As such, anxiety disorders should be regarded as a significant public health problem. However the causes of anxiety disorders remain largely unknown, which hinders accurate diagnosis, the prediction of prognosis, and the development of refined treatment approaches. In clinical practice, many patients with anxiety disorders do not present or are not recognised, the standard of care they receive is often sub-optimal, and the effectiveness of pharmacological and psychological treatment interventions in real-world clinical practice can be disappointing. The current substantial unmet public health, clinical and research needs in anxiety disorders could be addressed in part by developing independent collaborative European networks.
KW - Anxiety disorders
KW - Costs
KW - Impairment
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=84890161145&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2013.01.009
DO - 10.1016/j.neubiorev.2013.01.009
M3 - Review article
C2 - 23313646
AN - SCOPUS:84890161145
SN - 0149-7634
VL - 37
SP - 2312
EP - 2317
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
IS - 10
ER -